Bafilomycin A1 Accelerates Chronic Refractory Wound Healing in db/db Mice

Area of Science:

• Cell Biology
• Wound Healing Research
• Diabetic Complications

Background:

• Autophagy is crucial for chronic wound healing, with enhanced autophagy impairing the process.
• Autophagy inhibitors, like Bafilomycin A1 (Baf A1), prevent autophagosome formation.
• Diabetic chronic refractory wounds present a significant clinical challenge.

Purpose of the Study:

• To investigate the therapeutic effect of Bafilomycin A1 (Baf A1) on chronic refractory wound healing in diabetic mice.
• To elucidate the mechanisms by which Baf A1 influences wound repair in a diabetic model.

Main Methods:

• Diabetic (db/db) and non-diabetic (db/m) mice models were used.
• Full-thickness skin defects were created and treated with Baf A1 or left untreated.
• Wound healing, cell proliferation (PCNA), collagen deposition (Masson's trichrome), and cytokine expression (TNF-α, IL-10) were analyzed.

Main Results:

• Baf A1 treatment significantly accelerated wound healing in diabetic mice.
• Baf A1 inhibited epidermal autophagy and minimally affected overall metabolism.
• Increased PCNA expression and collagen thickness were observed in Baf A1-treated and control groups compared to untreated diabetic mice.
• Pro-inflammatory (TNF-α) and anti-inflammatory (IL-10) cytokine levels were modulated by Baf A1.

Conclusions:

• Bafilomycin A1 (Baf A1) demonstrates significant potential in accelerating diabetic chronic refractory wound healing.
• The mechanism involves promoting cell proliferation, enhancing collagen production, and rebalancing the inflammatory response.
• Baf A1 represents a promising therapeutic agent for managing complex diabetic wounds.